RESUMEN
Controversies exist with regard to in vivo approaches to delayed immunologically mediated adverse drug reactions, such as exanthem (maculopapular eruption), drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and fixed drug eruptions. In particular, widespread differences exist between regions and practice on the availability and use of intradermal and patch testing, the standard drug concentrations used, the use of additional drugs in intradermal and patch testing to help determine cross-reactivity, the timing of testing in relation to the occurrence of the adverse drug reaction, the use of testing in specific phenotypes, and the use of oral challenge in conjunction with delayed intradermal and patch testing to ascertain drug tolerance. It was noted that there have been advances in the science of delayed T cell-mediated reactions that have shed light on immunopathogenesis and provided a mechanism of preprescription screening in the case of HLA-B*57:01 and abacavir hypersensitivity and HLA-B*15:02 and carbamazepine Stevens-Johnson syndrome/toxic epidermal necrolysis in Southeast Asian subjects. Future directions should include the collaboration of large international networks to develop and standardize in vivo diagnostic approaches, such as skin testing and patch testing, combined with ex vivo and in vitro laboratory approaches.
Asunto(s)
Antígenos HLA-B , Antígeno HLA-B15 , Síndrome de Stevens-Johnson , Animales , Pueblo Asiatico , Carbamazepina/efectos adversos , Carbamazepina/uso terapéutico , Didesoxinucleósidos/efectos adversos , Didesoxinucleósidos/uso terapéutico , Antígenos HLA-B/genética , Antígenos HLA-B/inmunología , Antígeno HLA-B15/genética , Antígeno HLA-B15/inmunología , Humanos , Pruebas Cutáneas/normas , Síndrome de Stevens-Johnson/genética , Síndrome de Stevens-Johnson/inmunología , Síndrome de Stevens-Johnson/patologíaRESUMEN
Allergic reactions to drugs are a serious public health concern. In 2013, the Division of Allergy, Immunology, and Transplantation of the National Institute of Allergy and Infectious Diseases sponsored a workshop on drug allergy. International experts in the field of drug allergy with backgrounds in allergy, immunology, infectious diseases, dermatology, clinical pharmacology, and pharmacogenomics discussed the current state of drug allergy research. These experts were joined by representatives from several National Institutes of Health institutes and the US Food and Drug Administration. The participants identified important advances that make new research directions feasible and made suggestions for research priorities and for development of infrastructure to advance our knowledge of the mechanisms, diagnosis, management, and prevention of drug allergy. The workshop summary and recommendations are presented herein.
Asunto(s)
Hipersensibilidad a las Drogas/epidemiología , Síndrome de Stevens-Johnson/epidemiología , Investigación Biomédica Traslacional/tendencias , Virosis/epidemiología , Carbamazepina/efectos adversos , Didesoxinucleósidos/efectos adversos , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad a las Drogas/prevención & control , Expresión Génica , Antígenos HLA/genética , Antígenos HLA/inmunología , Haptenos/inmunología , Humanos , Inmunoglobulina E/sangre , National Institute of Allergy and Infectious Diseases (U.S.) , Guías de Práctica Clínica como Asunto , Receptores de Antígenos de Linfocitos T/genética , Receptores de Antígenos de Linfocitos T/inmunología , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/etiología , Síndrome de Stevens-Johnson/prevención & control , Terminología como Asunto , Estados Unidos/epidemiología , Virosis/diagnóstico , Virosis/inmunología , Virosis/prevención & controlRESUMEN
BACKGROUND: There is no consensus regarding treatment for drug reaction with eosinophilia and systemic symptoms (DRESS). OBJECTIVES: We report a single-center observational series of therapeutic management of DRESS. METHODS: We examined data for 50 consecutive patients admitted from March 2005 to June 2009 with a discharge diagnosis of DRESS (RegiSCAR score). RESULTS: For the 38 patients with a DRESS score of 4 or more, topical steroid treatment alone was initiated in 66% of cases. On admission, 13 patients received systemic steroids; in 7 of them, systemic steroid treatment was initiated or maintained for life-threatening organ failure, with kidney, lung, and/or nervous system involvement. Complications of DRESS, such as relapse, viral reactivation, and sepsis, were less frequent with topical steroid than with systemic steroids. None of the patients died during their stay in hospital. LIMITATIONS: Retrospective nonblinded design and dermatologic recruitment are limitations. The variables underlying the choice of treatment study were not analyzed. CONCLUSIONS: Systemic steroids may not be required for the management of mild forms of DRESS, and may thus be reserved for more severe cases. Prospective studies are required to evaluate strategies for treating DRESS.
Asunto(s)
Síndrome de Hipersensibilidad a Medicamentos/tratamiento farmacológico , Esteroides/administración & dosificación , Administración Tópica , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Síndrome de Hipersensibilidad a Medicamentos/diagnóstico , Síndrome de Hipersensibilidad a Medicamentos/etiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto JovenAsunto(s)
Alelos , Carbamazepina/efectos adversos , Predisposición Genética a la Enfermedad , Antígenos HLA-B/genética , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/etiología , Población Blanca/genética , Femenino , Estudios de Asociación Genética , Humanos , Masculino , FenotipoRESUMEN
BACKGROUND: The prognosis of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and SJS/TEN overlap syndrome has been assessed using a disease-specific severity score (SCORTEN) based on clinical and laboratory data. Histologic data may improve outcome prediction. OBJECTIVE: We sought to evaluate whether dermal mononuclear infiltration and epidermal necrosis predict survival of patients with TEN, SJS, or SJS/TEN. METHODS: We conducted a retrospective review of clinical records and skin biopsy specimens read without knowledge of clinical data. RESULTS: We identified 108 patients (SJS, n = 42; SJS/TEN, n = 36; TEN, n = 30). Overall mortality was 21.3%. Dermal infiltration and epidermal necrosis were not associated with time from disease onset to biopsy. Extensive dermal infiltrates were seen in 19 (18.5%) patients and full-thickness epidermal necrosis in 56 (52%) patients. Dermal infiltrate severity was not associated with day-1 (D1) SCORTEN or hospital death. Epidermal necrosis severity showed trends toward associations with D1 SCORTEN (P = .11) and hospital death (P = .06). In univariate analyses, full-thickness epidermal necrosis was significantly associated with hospital death (32.1% vs 11.4%, P = .017) and worse D1 SCORTEN values (1.98 ± 1.29 vs 1.55 ± 1.21; P = .04). In the bivariate analysis, however, D1 SCORTEN remained significantly associated with hospital death (odds ratio = 3.07, 95% confidence interval 1.83-5.16) but the association with full-thickness epidermal necrosis was no longer significant (odds ratio = 2.02, 95% confidence interval 0.65-7.12). LIMITATIONS: Retrospective study design and indirect assessment of progression are limitations. CONCLUSION: Full-thickness epidermal necrosis was associated with mortality but did not independently predict hospital death after adjustment based on the SCORTEN value. Dermal infiltrate severity was not associated with hospital death.
Asunto(s)
Síndrome de Stevens-Johnson/mortalidad , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Biopsia , Niño , Progresión de la Enfermedad , Epidermis/patología , Femenino , Mortalidad Hospitalaria , Humanos , Masculino , Persona de Mediana Edad , Necrosis/complicaciones , Pronóstico , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Síndrome de Stevens-Johnson/complicaciones , Síndrome de Stevens-Johnson/patologíaRESUMEN
Dermatological adverse events (AEs) are an existing concern during hepatitis C virus (HCV) infection and peginterferon/ribavirin treatment. HCV infection leads to dermatological and muco-cutaneous manifestations including small-vessel vasculitis as part of the mixed cryoglobulinemic syndrome. Peginterferon/ribavirin treatment is associated with well-characterized dermatological AEs tending towards a uniform entity of dermatitis. New direct-acting antivirals have led to significant improvements in sustained virologic response rates, but several have led to an increase in dermatological AEs versus peginterferon/ribavirin alone. In telaprevir trials, approximately half of treated patients had rash. More than 90% of these events were Grade 1 or 2 (mild/moderate) and in the majority (92%) of cases, progression to a more severe grade did not occur. In a small number of cases (6%), rash led to telaprevir discontinuation, whereupon symptoms commonly resolved. Dermatological AEs with telaprevir-based triple therapy were generally similar to those observed with peginterferon/ribavirin (xerosis, pruritus, and eczema). A few cases were classified as severe cutaneous adverse reaction (SCAR), also referred to as serious skin reactions, a group of rare conditions that are potentially life-threatening. It is therefore important to distinguish between telaprevir-related dermatitis and SCAR. The telaprevir prescribing information does not require telaprevir discontinuation for Grade 1 or 2 (mild/moderate) rash, which can be treated using emollients/moisturizers and topical corticosteroids. For Grade 3 rash, the prescribing information mandates immediate telaprevir discontinuation, with ribavirin interruption (with or without peginterferon) within 7 days of stopping telaprevir if there is no improvement, or sooner if it worsens. In case of suspicion or confirmed diagnosis of SCAR, all study medication must be discontinued.
Asunto(s)
Antivirales/efectos adversos , Erupciones por Medicamentos/etiología , Hepatitis C/complicaciones , Hepatitis C/tratamiento farmacológico , Enfermedades de la Piel/etiología , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/terapia , Humanos , Interferón-alfa/efectos adversos , Oligopéptidos/efectos adversos , Ribavirina/efectos adversosRESUMEN
Severe cutaneous adverse reactions include syndromes such as drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS) and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). An important advance has been the discovery of associations between HLA alleles and many of these syndromes, including abacavir-associated hypersensitivity reaction, allopurinol-associated DRESS/DIHS and SJS/TEN, and SJS/TEN associated with aromatic amine anticonvulsants. These HLA associations have created the promise for prevention through screening and have additionally shed further light on the immunopathogenesis of severe cutaneous adverse reactions. The rollout of HLA-B∗5701 into routine clinical practice as a genetic screening test to prevent abacavir hypersensitivity provides a translational roadmap for other drugs. Numerous hurdles exist in the widespread translation of several other drugs, such as carbamazepine, in which the positive predictive value of HLA-B∗1502 is low and the negative predictive value of HLA-B∗1502 for SJS/TEN might not be 100% in all ethnic groups. International collaborative consortia have been formed with the goal of developing phenotypic standardization and undertaking HLA and genome-wide analyses in diverse populations with these syndromes.
Asunto(s)
Hipersensibilidad a las Drogas/genética , Hipersensibilidad a las Drogas/inmunología , Antígenos HLA-B/genética , Anticonvulsivantes/efectos adversos , Ensayos Clínicos como Asunto , Inhibidores Enzimáticos/efectos adversos , Eosinofilia/inducido químicamente , Femenino , Pruebas Genéticas , Humanos , Masculino , Enfermedades de la Piel/genética , Enfermedades de la Piel/inmunologíaRESUMEN
Toxic epidermal necrolysis (TEN) is characterized by an acute detachment and destruction of keratinocytes, affecting large areas of the skin. It is often related to adverse drug reactions. Previous studies have shown that effector CD8+ T cells, which accumulate in the blister fluid, are functionally cytotoxic and act through a classical perforin/granzyme B pathway. It has recently been shown that these cytotoxic T cells also secrete granulysin peptide, which is lethal to keratinocytes. These cytotoxic T cells exert their killer activity against autologous keratinocytes in the presence of the drug. However, they are unlikely to be the only effectors of TEN. We therefore searched for soluble death factors in the blister fluids that might kill keratinocytes. We found that the amounts of interferon-γ, TRAIL and TNF-α proteins were significantly greater in TEN blister fluids than in all controls (normal sera, TEN sera, burns and Eosinophilic pustular folliculitis blister fluids) and TNF-like weak inducer of apoptosis (TWEAK) amounts are also greater in all controls except burns. We showed that these proteins acted in synergy to induce the death of keratinocytes in vitro. We also found that TRAIL and TWEAK were secreted by CD1a+ and CD14+ cells present in the blister fluids. Thus, in addition to MHC class I-restricted cytotoxic T lymphocytes (CTLs), which lyse keratinocytes, ligands secreted by non-lymphoid cells capable of inducing keratinocyte death in an MHC class I-independent manner, also seem to be present in the blister fluids of patients with TEN.
Asunto(s)
Antígenos CD1/metabolismo , Apoptosis , Vesícula/metabolismo , Queratinocitos/patología , Receptores de Lipopolisacáridos/metabolismo , Síndrome de Stevens-Johnson/metabolismo , Linfocitos T Citotóxicos/metabolismo , Ligando Inductor de Apoptosis Relacionado con TNF/metabolismo , Biopsia , Vesícula/patología , Estudios de Casos y Controles , Línea Celular , Proliferación Celular , Citocina TWEAK , Humanos , Interferón gamma/metabolismo , Síndrome de Stevens-Johnson/patología , Linfocitos T Citotóxicos/inmunología , Linfocitos T Citotóxicos/patología , Factor de Necrosis Tumoral alfa/metabolismo , Factores de Necrosis Tumoral/metabolismoRESUMEN
M. chelonae is a classical but uncommon etiology of nodular lymphangitis. We report 2 cases of nodular lymphangitis caused by M. chelonae occurring in immunocompromised hosts; both were cleared with antibiotic therapy.
Asunto(s)
Huésped Inmunocomprometido , Linfangitis/microbiología , Infecciones por Mycobacterium no Tuberculosas , Mycobacterium chelonae , Administración Oral , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Claritromicina/administración & dosificación , Esquema de Medicación , Quimioterapia Combinada , Femenino , Humanos , Inyecciones Intravenosas , Linfangitis/patología , Masculino , Persona de Mediana Edad , Minociclina/administración & dosificación , Minociclina/análogos & derivados , Tigeciclina , Tobramicina/administración & dosificación , Resultado del TratamientoRESUMEN
BACKGROUND: The combination of multiple cycles of rituximab and intravenous immune globulins has been reported to be effective in patients with severe pemphigus. The aim of this study was to assess the efficacy of a single cycle of rituximab in severe types of pemphigus. METHODS: We studied 21 patients with pemphigus whose disease had not responded to an 8-week course of 1.5 mg of prednisone per kilogram of body weight per day (corticosteroid-refractory disease), who had had at least two relapses despite doses of prednisone higher than 20 mg per day (corticosteroid-dependent disease), or who had severe contraindications to corticosteroids. The patients were treated with four weekly infusions of 375 mg of rituximab per square meter of body-surface area. The primary end point was complete remission 3 months after the end of rituximab treatment; complete remission was defined as epithelialization of all skin and mucosal lesions. RESULTS: Eighteen of 21 patients (86%; 95% confidence interval, 64 to 97%) had a complete remission at 3 months. The disease relapsed in nine patients after a mean of 18.9+/-7.9 months. After a median follow-up of 34 months, 18 patients (86%) were free of disease, including 8 who were not receiving corticosteroids; the mean prednisone dose decreased from 94.0+/-10.2 to 12.0+/-7.5 mg per day (P=0.04) in patients with corticosteroid-refractory disease and from 29.1+/-12.4 to 10.9+/-16.5 mg per day (P=0.007) in patients with corticosteroid-dependent disease. Pyelonephritis developed in one patient 12 months after rituximab treatment, and one patient died of septicemia 18 months after rituximab treatment. These patients had a profound decrease in the number of circulating B lymphocytes but normal serum levels of IgG. CONCLUSIONS: A single cycle of rituximab is an effective treatment for pemphigus. Because of its potentially severe side effects, its use should be limited to the most severe types of the disease. (ClinicalTrials.gov number, NCT00213512 [ClinicalTrials.gov].).
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Factores Inmunológicos/administración & dosificación , Pénfigo/tratamiento farmacológico , Anciano , Antiinflamatorios/administración & dosificación , Anticuerpos/sangre , Anticuerpos Monoclonales de Origen Murino , Linfocitos B , Desmogleínas/inmunología , Esquema de Medicación , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Isotipos de Inmunoglobulinas/sangre , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Pénfigo/inmunología , Prednisona/administración & dosificación , Inducción de Remisión , RituximabRESUMEN
Fixed drug eruption (FDE) is one of the most typical cutaneous drug adverse reactions. This localized drug-induced reaction is characterized by its relapse at the same sites. Few large series of FDE are reported. The aim of this study was to retrospectively collect and analyse well informed cases observed in a hospital setting. This study involved 17 academic clinical centers. A French nation-wide retrospective multicentric study was carried out on a 3-year-period from 2005 to 2007 by collecting data in seventeen departments of dermatology in France. Diagnosis of FDE was based essentially on clinical findings, at times confirmed by pathological data and patch-testing. Records were reviewed for demographics, causative drugs, localization, severity, and patch-tests, when available. Fifty nine cases were analysed. Patients were 59-years-old on average, with a female predilection. The most common drug was paracetamol, followed by the non-steroidal anti inflammatory drugs. The time between drug intake and skin symptoms was, on average, two days. Beside these classical characteristics, some original findings were found including, a frequent non pigmentation course and a sex-dependent pattern of distribution. Women often had lesions on the hands and feet, and men on the genitalia. Given the fact that skin pigmentation is an inconstant feature of FDE, its French name (erythème pigmenté fixe) should be reconsidered. The sex-dependent distribution could help our understanding of the pathophysiology of fixed drug eruption.
Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Erupciones por Medicamentos/epidemiología , Acetaminofén/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Analgésicos/efectos adversos , Análisis de Varianza , Antibacterianos/efectos adversos , Antiinflamatorios no Esteroideos/efectos adversos , Niño , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/etiología , Femenino , Francia/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Pruebas del Parche , Estudios RetrospectivosRESUMEN
Drug hypersensitivity such as severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), could be life-threatening. Here, we enroll SCAR patients to investigate the T cell receptor (TCR) repertoire by next-generation sequencing. A public αßTCR is identified from the cytotoxic T lymphocytes of patients with carbamazepine-SJS/TEN, with its expression showing drug/phenotype-specificity and an bias for HLA-B*15:02. This public αßTCR has binding affinity for carbamazepine and its structural analogs, thereby mediating the immune response. Adoptive transfer of T cell expressing this public αßTCR to HLA-B*15:02 transgenic mice receiving oral administration of carbamazepine induces multi-organ injuries and symptoms mimicking SCAR, including hair loss, erythema, increase of inflammatory lymphocytes in the skin and blood, and liver and kidney dysfunction. Our results not only demonstrate an essential role of TCR in the immune synapse mediating SCAR, but also implicate potential clinical applications and development of therapeutics.
Asunto(s)
Carbamazepina/efectos adversos , Complejo Receptor-CD3 del Antígeno de Linfocito T/metabolismo , Receptores de Antígenos de Linfocitos T alfa-beta/metabolismo , Síndrome de Stevens-Johnson/inmunología , Linfocitos T Citotóxicos/inmunología , Traslado Adoptivo , Adulto , Anciano , Animales , Modelos Animales de Enfermedad , Femenino , Antígeno HLA-B15/genética , Antígeno HLA-B15/inmunología , Humanos , Masculino , Ratones Transgénicos , Persona de Mediana Edad , Complejo Receptor-CD3 del Antígeno de Linfocito T/inmunología , Receptores de Antígenos de Linfocitos T alfa-beta/inmunología , Índice de Severidad de la Enfermedad , Piel/inmunología , Piel/patología , Síndrome de Stevens-Johnson/diagnóstico , Síndrome de Stevens-Johnson/patología , Linfocitos T Citotóxicos/metabolismo , Linfocitos T Citotóxicos/trasplanteRESUMEN
BACKGROUND: No treatment modality has been established as standard for patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. OBJECTIVE: We sought to evaluate the effect of treatment on mortality in a large cohort of patients with Stevens-Johnson syndrome or toxic epidermal necrolysis. METHODS: Data on therapy were retrospectively collected from patients in France and Germany enrolled in EuroSCAR, a case-control study of risk factors. RESULTS: Neither intravenous immunoglobulins nor corticosteroids showed any significant effect on mortality in comparison with supportive care only. Compared with supportive care, odds ratios for death were 1.4 (95% confidence interval: 0.6-4.3) for intravenous immunoglobulins in France and 1.5 (0.5-4.4) in Germany, and 0.4 (0.1-1.7) for corticosteroids in France and 0.3 (0.1-1.1) in Germany. LIMITATIONS: Such an observational study with retrospective data collection has obvious limitations, including heterogeneity between the countries, supportive care, treatment doses, and durations. CONCLUSIONS: We found no sufficient evidence of a benefit for any specific treatment. The trend for a beneficial effect of corticosteroids deserves further exploration.
Asunto(s)
Corticoesteroides/uso terapéutico , Inmunoglobulinas Intravenosas/uso terapéutico , Síndrome de Stevens-Johnson/tratamiento farmacológico , Síndrome de Stevens-Johnson/mortalidad , Adulto , Anciano , Estudios de Casos y Controles , Estudios de Cohortes , Femenino , Francia , Alemania , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Estudios RetrospectivosRESUMEN
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare severe cutaneous adverse reactions. OBJECTIVES: We sought to update knowledge on the causes of SJS or TEN with a focus on the rate of allopurinol-associated cases and to identify risk factors for allopurinol-associated SJS or TEN. METHODS: We conducted a multinational case-control study. RESULTS: In all, 379 patients with severe cutaneous adverse reactions validated as SJS or TEN and 1505 matched hospitalized control subjects were enrolled. Allopurinol was the drug most frequently associated with SJS or TEN, with 66 exposed patients (17.4%) and 28 exposed control subjects (1.9%) (adjusted odds ratio = 18, 95% confidence interval: 11-32). Allopurinol use was greater than in a previous case-control European study. Daily doses equal to or greater than 200 mg were associated with a higher risk (adjusted odds ratio = 36, 95% confidence interval: 17-76) than lower doses (adjusted odds ratio = 3.0, 95% confidence interval: 1.1-8.4). The risk was restricted to short-term use (Asunto(s)
Alopurinol/efectos adversos
, Supresores de la Gota/efectos adversos
, Síndrome de Stevens-Johnson/inducido químicamente
, Síndrome de Stevens-Johnson/etiología
, Adulto
, Anciano
, Alopurinol/administración & dosificación
, Alopurinol/uso terapéutico
, Estudios de Casos y Controles
, Demografía
, Relación Dosis-Respuesta a Droga
, Esquema de Medicación
, Quimioterapia Combinada
, Europa (Continente)/epidemiología
, Femenino
, Supresores de la Gota/administración & dosificación
, Supresores de la Gota/uso terapéutico
, Humanos
, Incidencia
, Israel/epidemiología
, Masculino
, Persona de Mediana Edad
, Vigilancia de la Población
, Síndrome de Stevens-Johnson/epidemiología
RESUMEN
BACKGROUND: Conflicting opinions have been reported regarding the epidemiology of hidradenitis suppurativa. OBJECTIVE: We sought to evaluate the prevalence of hidradenitis suppurativa and to identify associated factors. METHODOLOGY: Prevalence was evaluated using a representative sample of the French population (n=10,000). Associated risk factors were assessed using two case-control studies, one population-based with 67 self-reported patients and 200 control subjects, and the other clinic-based with 302 medically assessed patients and 906 control subjects. RESULTS: The prevalence was 1% of the French population. Multivariate analyses showed a strong association with current smoking in self-reported (odds ratio=4.16, 95% confidence interval [2.99-8.69]) and in medically assessed (odds ratio=12.55 [8.58-18.38]) populations. Association with body mass index was significant in medically assessed patients (odds ratio=1.12 [1.08-1.15]) for each increase of 1 U of BMI. LIMITATIONS: A causal relationship could not be established with such a cross-sectional study. CONCLUSION: Hidradenitis suppurativa is a common disease, frequently associated with smoking and being overweight.
Asunto(s)
Hidradenitis Supurativa/epidemiología , Adulto , Consumo de Bebidas Alcohólicas/epidemiología , Estudios de Casos y Controles , Causalidad , Comorbilidad , Femenino , Francia/epidemiología , Humanos , Masculino , Análisis Multivariante , Obesidad/epidemiología , Oportunidad Relativa , Prevalencia , Factores de Riesgo , Fumar/epidemiologíaRESUMEN
BACKGROUND: Minocycline-induced drug rash with eosinophilia and systemic symptoms (DRESS) may have a prolonged course, especially in African and African-American patients. OBJECTIVES: To determine if a prolonged course of minocycline-induced DRESS was associated with an accumulation of the culprit drug. PATIENTS AND METHODS: We determined plasma and skin levels of minocycline in patients with minocycline-induced DRESS. We investigated the genetic polymorphisms of enzymes potentially involved in the detoxification of the drug, glutathione S-transferases and UDP-glucuronosyltransferases. RESULTS AND CONCLUSIONS: We demonstrated the persistence of minocycline in the plasma and/or in the skin of 7 out of 9 patients with skin phototypes V-VI. As pigmented skin contains more melanin, this could promote the formation of a melanin-minocycline complex, which could explain the severe and prolonged DRESS which may occur in this subgroup of patients.
Asunto(s)
Antibacterianos/efectos adversos , Población Negra , Hipersensibilidad a las Drogas/genética , Eosinofilia/inducido químicamente , Glutatión Transferasa/genética , Minociclina/efectos adversos , Acné Vulgar/tratamiento farmacológico , Adolescente , Adulto , Antibacterianos/farmacocinética , Cromatografía Líquida de Alta Presión , Hipersensibilidad a las Drogas/enzimología , Hipersensibilidad a las Drogas/etnología , Eosinofilia/etnología , Eosinofilia/genética , Femenino , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Masculino , Melaninas/análisis , Persona de Mediana Edad , Minociclina/farmacocinética , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Eliminación de Secuencia , Piel/patología , Pigmentación de la Piel , SíndromeRESUMEN
Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN.
Asunto(s)
Testimonio de Experto , Síndrome de Stevens-Johnson/epidemiología , Anciano , Niño , Congresos como Asunto , Diagnóstico Precoz , Registros Electrónicos de Salud , Femenino , Humanos , Comunicación Interdisciplinaria , Masculino , Embarazo , Síndrome de Stevens-Johnson/tratamiento farmacológico , Síndrome de Stevens-Johnson/inmunología , Investigación Biomédica Traslacional , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: Bullous pemphigoid is the most common autoimmune blistering skin disease of the elderly. Because elderly people have low tolerance for standard regimens of oral corticosteroids, we studied whether highly potent topical corticosteroids could decrease mortality while controlling disease. METHODS: A total of 341 patients with bullous pemphigoid were enrolled in a randomized, multicenter trial and stratified according to the severity of their disease (moderate or extensive). Patients were randomly assigned to receive either topical clobetasol propionate cream (40 g per day) or oral prednisone (0.5 mg per kilogram of body weight per day for those with moderate disease and 1 mg per kilogram per day for those with extensive disease). The primary end point was overall survival. RESULTS: Among the 188 patients with extensive bullous pemphigoid, topical corticosteroids were superior to oral prednisone (P=0.02). The one-year survival rate was 76 percent in the topical-corticosteroid group and 58 percent in the oral-prednisone group. Disease was controlled at three weeks in 92 of the 93 patients in the topical-corticosteroid group (99 percent) and 86 of the 95 patients in the oral-prednisone group (91 percent, P=0.02). Severe complications occurred in 27 of the 93 patients in the topical-corticosteroid group (29 percent) and in 51 of the 95 patients in the oral-prednisone group (54 percent, P=0.006). Among the 153 patients with moderate bullous pemphigoid, there were no significant differences between the topical-corticosteroid group and the oral-prednisone group in terms of overall survival, the rate of control at three weeks, or the incidence of severe complications. CONCLUSIONS: Topical corticosteroid therapy is effective for both moderate and severe bullous pemphigoid and is superior to oral corticosteroid therapy for extensive disease.
Asunto(s)
Clobetasol/administración & dosificación , Glucocorticoides/administración & dosificación , Penfigoide Ampolloso/tratamiento farmacológico , Prednisona/administración & dosificación , Administración Oral , Administración Tópica , Anciano , Anciano de 80 o más Años , Clobetasol/efectos adversos , Glucocorticoides/efectos adversos , Hospitalización , Humanos , Tiempo de Internación , Pomadas , Penfigoide Ampolloso/clasificación , Penfigoide Ampolloso/mortalidad , Prednisona/efectos adversos , Modelos de Riesgos Proporcionales , Recurrencia , Tasa de SupervivenciaRESUMEN
Drug eruptions are among the most common adverse drug reactions, affecting approximately 3% of hospitalised patients. Although the rate of severe cutaneous adverse reactions to medications is low, these reactions can affect anyone who takes medication, and can result in death or disability. Two general patterns can be distinguished, depending on the type of onset of these cutaneous adverse drug reactions: acute or chronic. Acute-onset events are usually rather specific cutaneous 'syndromes' that constitute emergencies and should therefore be promptly recognised and treated, while chronic-onset events often present as dermatological diseases. The challenge is therefore to recognise the drug aetiology in front of a 'classical' dermatosis such as acne, lichen or pemphigus. Therefore, clinicians should carefully evaluate the signs or symptoms of all adverse reactions thought to be drug related, and discontinue the offending agent when feasible. Erythematous drug eruptions are the most frequent and less severe acute immune drug-induced rashes, and are sometimes difficult to differentiate from viral eruptions. On the other hand, acute urticaria and angioedema are sometimes life-threatening eruptions for which a drug aetiology must be investigated. Photosensitivity, vasculitis and skin necrosis belong to the acute onset reactions, which are not always drug-induced, in contrast to fixed drug eruptions. The early recognition of acute generalised exanthematous pustulosis, DRESS (drug reaction with eosinophilia and systemic symptoms) syndrome, Stevens-Johnson syndrome and toxic epidermal necrolysis are of high importance because of the specific mechanisms involved and the different prognosis of each of these diseases. Chronic onset drug-induced disorders include pigmentary changes, drug-induced autoimmune bullous diseases, lupus, pseudo lymphoma and acneiform eruptions; these are discussed, along with specific data on drug-induced hair and nail disorders. As the disorders are numerous, the mechanisms and the drugs involved in the development of these various reactions are multiple. The list of drugs discussed in relation to the different disorders are as accurate as possible at the time of preparation of this review, but will need updating as new drugs emerge onto the market. We emphasize the clinical recognition, pathophysiology and treatment of skin, hair and nail adverse drug reactions, and the role of each doctor involved in the management of these patients in the notification of the adverse drug reaction to health authorities, using the minimal requirement for notification proposed.